Last reviewed · How we verify
NCT04380987: Predi-COVID
Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis
trial testing Biological sampling in Covid19 in 1,366 participants. Completed in 30 September 2024.
30 September 2024
Quick facts
| Lead sponsor | Luxembourg Institute of Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,366 |
| Start date | 4 May 2020 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across Luxembourg |
Drugs / interventions tested
- Biological sampling — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Luxembourg Institute of Health
Who can join
18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Predi-COVID is a prospective cohort study composed of people positively tested for COVID-19 in Luxembourg, followed digitally for monitoring participants' health evolution and symptoms at home. Participants will be actively followed for 14 days from the time of confirmation of diagnosis, whether they are at the hospital or at home in isolation or quarantine. Short evaluations will be also performed at week 3 and week 4 and then monthly for a period up to 12 months to assess potential long term consequences of COVID-19. A subsample of 200 participants will be contacted to integrate complementary clinical data and collect samples. The study aims at identifying factors associated with the COVID-19 disease severity. COVID-19 patients with severity criteria will be compared to patients with mild disease managed at home. A deep phenotyping related to the symptoms of the disease as well as biosampling allowing for laboratory-based and computational analytics will be performed.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Long COVID Symptomatology After 12 Months and Its Impact on Quality of Life According to Initial Coronavirus Disease 2019 Disease Severity.
Fischer A, Fischer A, Zhang L, Elbéji A, et al · · 2022 · cited 42× · PMID 35983269 · DOI 10.1093/ofid/ofac397 -
Protocol for a prospective, longitudinal cohort of people with COVID-19 and their household members to study factors associated with disease severity: the Predi-COVID study.
Fagherazzi G, Fischer A, Betsou F, Vaillant M, et al · · 2020 · cited 24× · PMID 33234656 · DOI 10.1136/bmjopen-2020-041834 -
Development of a long noncoding RNA-based machine learning model to predict COVID-19 in-hospital mortality.
Devaux Y, Zhang L, Lumley AI, Karaduzovic-Hadziabdic K, et al · · 2024 · cited 16× · PMID 38769334 · DOI 10.1038/s41467-024-47557-1 -
Vocal biomarker predicts fatigue in people with COVID-19: results from the prospective Predi-COVID cohort study.
Elbéji A, Zhang L, Higa E, Fischer A, et al · · 2022 · cited 14× · PMID 36414294 · DOI 10.1136/bmjopen-2022-062463 -
Associations between physical activity prior to infection and COVID-19 disease severity and symptoms: results from the prospective Predi-COVID cohort study.
Malisoux L, Backes A, Fischer A, Aguayo G, et al · · 2022 · cited 13× · PMID 35487745 · DOI 10.1136/bmjopen-2021-057863 -
Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients.
Capelle CM, Ciré S, Domingues O, Ernens I, et al · · 2022 · cited 13× · PMID 35480624 · DOI 10.1016/j.xcrm.2022.100600 -
A voice-based biomarker for monitoring symptom resolution in adults with COVID-19: Findings from the prospective Predi-COVID cohort study.
Fagherazzi G, Zhang L, Elbéji A, Higa E, et al · · 2022 · cited 7× · PMID 36812535 · DOI 10.1371/journal.pdig.0000112 -
Discovery and Analytical Validation of a Vocal Biomarker to Monitor Anosmia and Ageusia in Patients With COVID-19: Cross-sectional Study.
Higa E, Elbéji A, Zhang L, Fischer A, et al · · 2022 · cited 7× · PMID 36265042 · DOI 10.2196/35622
Verify or expand the search:
- PubMed search for NCT04380987
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biological sampling
Trials testing the same drug.
- NCT05970965 — Periodontitis and Inflammation in Children With Down Syndrome/Trisomy 21: Study on Biological Samples · NA · recruiting
- NCT06890078 — Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients · not yet recruiting
- NCT06828458 — Determining Elements of Anti-Fungal Immunity in BURN Patients · not yet recruiting
- NCT06690151 — Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal · recruiting
- NCT07017348 — Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis · NA · completed
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Luxembourg Institute of Health trials
Trials by the same sponsor.
- NCT07500259 — Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and P · not yet recruiting
- NCT06235684 — Clinnova-RD: A Prospective Cohort Study of Patients With Rheumatoid Diseases · not yet recruiting
- NCT07156994 — Development of Voice Biomarkers of Frequent COVID-19 and Long Covid-related Symptoms Based on Data From Users of the Lon · not yet recruiting
- NCT06816147 — HealthyW8_60+ Pilot · NA · recruiting
- NCT06384872 — Effect of Shoe Cushioning Position and Properties on Running-related Injury Risk · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04380987 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Luxembourg Institute of Health
- Last refreshed: 9 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04380987.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing